25 terminated. 25 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Terminated 25 |
| Phase 1 | 9 | Terminated 9 |
Follow pomalidomide: new trials by email Literature Review of pomalidomide trials Research Report on pomalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Bone Marrow Biopsy, Dexamethasone, Lenalidomide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Terminated | Mayo Clinic | 17 | 2022-06-15 | 2026-09-28 |
| A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma Daratumumab, Pomalidomide, All-trans retinoic acid - Multiple Myeloma | Phase 2 | Terminated | Hackensack Meridian Health | 1 | 2022-05-02 | 2025-02-25 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Selinexor, Clarithromycin, Pomalidomide - Myeloma Multiple, Myeloma | Phase 2 | Terminated | Weill Medical College of Cornell University | 4 | 2021-12-29 | 2023-10-25 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma Magrolimab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 2 | Terminated | Gilead Sciences | 36 | 2021-11-09 | 2025-05-02 |
| Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis daratumumab and pomalidomide - AL Amyloidosis | Phase 2 | Terminated | Fondazione IRCCS Policlinico San Matteo di Pavia | 27 | 2021-06-23 | 2025-02-20 |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone - Multiple Myeloma, Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Multiple Myeloma Research Consortium | 14 | 2020-07-10 | 2025-02-14 |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas DTRM-555 - Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Zhejiang DTRM Biopharma | 55 | 2020-04-24 | 2025-01-08 |
| A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Venetoclax, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Terminated | AbbVie | 8 | 2018-10-18 | 2021-06-30 |
| Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma Ixazomib, Pomalidomide, Dexamethasone - Relapsed/Refractory Multiple Myeloma | Phase 2 | Terminated | University of California, San Diego | 23 | 2018-10-17 | 2025-10-21 |
| Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma Pomalidomide, Dexamethasone - Refractory Multiple Myeloma | Phase 2 | Terminated | Swiss Cancer Institute | 34 | 2018-10-01 | 2021-06-10 |
| Combination Study for High Risk Multiple Myeloma Patients Elotuzumab, Pomalidomide, Carfilzomib - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 13 | 2017-03-13 | 2022-03-31 |
| Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib Pomalidomide + Cyclophosphamide + Dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Maimónides Biomedical Research Institute of Córdoba | 6 | 2017-02-23 | 2020-01-28 |
| A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma Daratumumab, Durvalumab, Pomalidomide - Multiple Myeloma | Phase 2 | Terminated | Celgene | 37 | 2016-07-07 | 2023-02-21 |
| Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma Ibrutinib, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Pharmacyclics LLC. | 11 | 2016-03-01 | 2019-11-21 |
| 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma MK-3475, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Ashraf Badros | 48 | 2014-12-30 | 2019-11-05 |
| Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib Carfilzomib, Dexamethasone, Prednisone - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 45 | 2014-12-01 | 2023-11-01 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies INCB052793, gemcitabine, nab-paclitaxel - Solid Tumors, Advanced Malignancies | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 83 | 2014-09-10 | 2020-04-17 |
| Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients POM, Steroids, PLD - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 45 | 2014-07-07 | 2023-11-03 |
| Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis - Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 21 | 2014-03-05 | 2021-07-30 |
| ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Celgene | 103 | 2014-03-01 | 2025-03-04 |
Showing 20 of 25. Sign in to see all of them.
Multiple Myeloma (19) · Recurrence (5) · Neoplasms (4) · Neoplasms, Plasma Cell (2) · Blood Protein Disorders (1) · Carcinoma, Small Cell (1) · Hematologic Diseases (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Diseases, Interstitial (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1)
Celgene (5) · Oncotherapeutics (3) · Weill Medical College of Cornell University (2) · AbbVie (1) · Ashraf Badros (1) · Criterium, Inc. (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Gilead Sciences (1) · Hackensack Meridian Health (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Mayo Clinic (1) · Multiple Myeloma Research Consortium (1) · Pharmacyclics LLC. (1)
United States (22) · Spain (5) · Canada (3) · Germany (3) · Italy (3) · United Kingdom (3) · Australia (2) · Czechia (2) · Switzerland (2) · Belgium (1) · Denmark (1) · France (1) · Greece (1) · Poland (1) · Russia (1)
James R Berenson, MD (3) · Abderrahim Fandi, MD (1) · Ashraf Z Badros, M.B.,Ch.B (1) · Brian GM Durie, MD (1) · Caitlin Costello, MD (1) · Christoph Driessen, Prof (1) · Christoph Renner, Prof (1) · Ekaterine Asatiani, M.D. (1) · Hearn J. Cho, M.D., Ph.D. (1) · Jatin Shah, MD (1) · Jorge Monge, MD (1)
PMID 23370364, PMID 26384354, PMID 28461396, PMID 34551886, PMID 34818965, PMID 39187595, PMID 40485906
2017 (1)